Home / Market News / $GILD

$GILD news and market catalysts

The 47 most recent market catalysts affecting $GILD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

47 catalysts 5 high impact 32 bullish 6 bearish Pharmaceuticals
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
Gilead Sciences Signs Voluntary Licensing Agreements for Investigational Antiviral Obeldesivir
Gilead Sciences announced voluntary licensing agreements for its investigational Ebola drug, obeldesivir, with generic manufacturers. This move is primarily a humanitarian effort t…
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
Barclays Adjusts Price Target on Gilead Sciences to $160 From $145
Barclays has raised its price target for Gilead Sciences from $145 to $160, signaling increased confidence in the biopharmaceutical company's valuation. This upgrade is a positive …
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
HSBC Adjusts Price Target on Gilead Sciences to $190 From $175
HSBC's decision to raise its price target for Gilead Sciences from $175 to $190 signals a more favorable view from a prominent financial institution. This matters because analyst p…
Nov 12, 2026 Corporate Catalyst Bullish Impact 55
Argus Research Upgrades Gilead Sciences Price Target
Argus Research has upgraded its price target for Gilead Sciences (GILD) from $165 to $190, while keeping its 'Buy' rating. This indicates a more bullish stance from the analyst on …
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Daiwa Securities Adjusts Gilead Sciences Price Target to $174 From $150
Daiwa Securities has raised its price target for Gilead Sciences (GILD) from $150 to $174. This adjustment reflects an improved analyst outlook on the company's valuation and futur…
Nov 7, 2026 Corporate Catalyst Neutral Impact 65
Gilead Sciences Awaits FDA Decision on New Cell Therapy
Gilead Sciences has filed an 8-K disclosing that it is awaiting an FDA decision on a new cell therapy product. This is a significant regulatory milestone for the company, as the ap…
Nov 6, 2026 Corporate Catalyst Bullish Impact 75
Gilead Sciences Announces Positive Results from PURPOSE 5 Trial for Lenacapavir
Gilead Sciences reported highly favorable results from its PURPOSE 5 trial for lenacapavir, showing superior persistence and complete efficacy in preventing HIV acquisition compare…
Nov 5, 2026 Corporate Catalyst Bullish Impact 75
Gilead Sciences Announces Phase 3 IDEAL Study Results for Livdelzi in PBC
Gilead Sciences announced positive detailed results from its Phase 3 IDEAL study for Livdelzi (seladelpar) in Primary Biliary Cholangitis (PBC). The study met its primary endpoint,…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
Maxim Group Raises Gilead Sciences Price Target to $200
Maxim Group has raised its price target for Gilead Sciences (GILD) from $165 to $200, reflecting a revised and more favorable valuation of the company. This analyst upgrade signals…
Nov 4, 2026 Corporate Catalyst Neutral Impact 55
Gilead Sciences and Kite Announce Clinical Data Presentations for ASH 2026
Gilead Sciences and Kite are announcing their participation and planned presentations at the American Society of Hematology (ASH) Annual Meeting in December 2026. This matters beca…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
DZ Bank has raised its price target for Gilead Sciences (GILD) from $167 to $191. This upward revision signals increased confidence from the analyst firm in Gilead's future prospec…
Nov 2, 2026 Corporate Catalyst Bullish Impact 75
FDA Approves Long-Acting HIV Prevention Drug
The FDA has approved Gilead Sciences' lenacapavir as a long-acting injectable for HIV prevention, administered twice yearly. This is a significant development as it offers a less f…
Nov 2, 2026 Corporate Catalyst Bullish Impact 65
FDA Grants Tentative Approval for Generic Lenacapavir for HIV Prevention in Global Markets
The FDA has issued a tentative approval for a generic version of Gilead Sciences' lenacapavir, an injectable drug for HIV prevention. This approval is specifically for distribution…
Nov 2, 2026 Corporate Catalyst Neutral Impact 55
Gilead Sciences to Present Clinical Data at HIV Glasgow 2026
Gilead Sciences has announced its intention to present extensive clinical data and real-world evidence from over 50 HIV studies at the HIV Glasgow 2026 conference. This event, sche…
Nov 2, 2026 Corporate Catalyst Bullish Impact 55
Bernstein Increases Price Target for Gilead Sciences
Bernstein, a prominent financial services firm, has raised its price target for Gilead Sciences from $160 to $175. This upward revision signals a more favorable view of Gilead's fi…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts Gilead Sciences Price Target to $195 From $175, Maintains Buy Rating
UBS has adjusted its price target for Gilead Sciences upwards from $175 to $195, while simultaneously maintaining its 'Buy' rating on the stock. This action suggests that UBS analy…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Markets Raises Price Target on Gilead Sciences
RBC Capital Markets has raised its price target for Gilead Sciences (GILD) from $126 to $131. This indicates a slightly more optimistic outlook from the analyst firm regarding Gile…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Cantor Fitzgerald and Needham Update Gilead Sciences Ratings
Following Gilead Sciences' third-quarter 2026 earnings, two prominent investment firms, Cantor Fitzgerald and Needham, updated their ratings and price targets. Cantor Fitzgerald ma…
Oct 29, 2026 Corporate Catalyst Bullish Impact 85
Gilead Sciences Announces Third Quarter 2026 Financial Results
Gilead Sciences announced Q3 2026 results that significantly beat analyst expectations for both revenue and adjusted EPS. This strong performance, described by the CEO as the best …
Oct 27, 2026 Corporate Catalyst Bullish Impact 60
Gilead Reaches Milestone National Agreement for LYVDELZI® (seladelpar) in Canada
Gilead Sciences has successfully completed pan-Canadian negotiations for LYVDELZI® (seladelpar), a treatment for primary biliary cholangitis (PBC). This agreement is crucial as it …
Oct 23, 2026 Corporate Catalyst Neutral Impact 92
Lazard Acts as Financial Advisor to Gilead Sciences in $1.275 Billion Acquisition of PepStar Program
Gilead Sciences announced a definitive agreement to acquire PepStar Therapeutics' IL-23R inhibitor program for $1.275 billion in upfront cash. This is a significant strategic move …
Oct 22, 2026 Corporate Catalyst Bullish Impact 55
Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement
Gilead Sciences has agreed to pay $45 million to the state of Texas to resolve allegations concerning its Medicaid activities. This settlement concludes a legal matter, which is ge…
Oct 22, 2026 Corporate Catalyst Neutral Impact 65
Gilead Sciences to Present New Clinical Data at The Liver Meeting 2026
Gilead Sciences is set to present 21 abstracts at The Liver Meeting 2026, with a focus on late-breaking Phase 3 data for Livdelzi (seladelpar) in primary biliary cholangitis (PBC) …
Oct 20, 2026 Corporate Catalyst Bullish Impact 55
B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172
B of A Securities analyst Tim Anderson maintained a 'Buy' rating on Gilead Sciences (GILD) and raised the price target from $168 to $172. This action signals continued confidence i…
Oct 19, 2026 Corporate Catalyst Bullish Impact 75
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success
Gilead's announcement of positive Phase 2 trial results for emvistegrast in ulcerative colitis is a significant corporate catalyst. The drug met its primary efficacy endpoint and s…
Oct 19, 2026 Corporate Catalyst Neutral Impact 75
Gilead Announces Emvistegrast 200 Mg Met Primary Endpoint In Phase 2 Swift Dose-Ranging Study; Demonstrated Significant Differences Across Multiple Secondary Measures Of Disease Activity Based On Nominal P-Values; Plans To Initiate Phase 3 Emvistegrast Monotherapy Study In 2027
Gilead announced positive results for its Emvistegrast 200 mg drug in a Phase 2 dose-ranging study, where it met its primary endpoint and showed significant differences in multiple…
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170
JP Morgan analyst Chris Schott has maintained an 'Overweight' rating on Gilead Sciences and raised the price target from $160 to $170. This action signals continued confidence from…
Oct 7, 2026 Corporate Catalyst Bearish Impact 55
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163
Morgan Stanley's analyst Matthew Harrison maintained an 'Overweight' rating on Gilead Sciences, signaling a continued positive long-term outlook for the company. However, the sligh…
Sep 30, 2026 Macro/Central Bank Bearish Impact 55
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
Former President Bill Clinton's warning about HIV funding cuts underscores a significant risk to global health initiatives and the pharmaceutical companies involved in developing a…
Sep 16, 2026 Corporate Catalyst Bullish Impact 75
Gilead Sciences Announces Expansion Of Six Royalty-Free Voluntary Licensing Agreements To Cover Once-Yearly Lenacapavir For HIV Prevention Across 120 Countries
Gilead's expansion of royalty-free licensing for Lenacapavir is a significant positive for the company, as it broadens the drug's availability for HIV prevention across 120 countri…
Sep 15, 2026 Corporate Catalyst Bullish Impact 55
Gilead And PAHO Partner To Expand Twice-Yearly Lenacapavir HIV Prevention Access Across Latin America And The Caribbean
Gilead Sciences has entered into an agreement with the Pan American Health Organization (PAHO) to facilitate broader access to its long-acting HIV prevention drug, lenacapavir, acr…
Sep 15, 2026 Corporate Catalyst Bullish Impact 65
Gilead Exec Says HIV Market Growth Should Normalize To 2%-3% Within Next Couple Of Quarters
A Gilead Sciences executive, likely during an investor event or conference call referenced by the webcast link, stated that the HIV market growth rate is anticipated to normalize t…
Sep 15, 2026 Corporate Catalyst Neutral Impact 65
Gilead Sciences Exec Says Weekly Oral HIV Prevention Drug Expected To Launch In Q1 2027
Gilead Sciences, a major player in HIV treatment and prevention, has provided a specific timeline for the launch of its weekly oral HIV prevention drug: Q1 2027. This announcement,…
Sep 10, 2026 Corporate Catalyst Bullish Impact 55
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175
HSBC's analyst Morten Herholdt maintaining a 'Buy' rating and raising the price target for Gilead Sciences from $155 to $175 indicates increased confidence in the company's financi…
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
FDA Approves Gilead's New Single Tablet HIV Regimen
The FDA approval of Gilead's Bixlenvo is a significant positive development for the company. Bixlenvo offers the first and only single-tablet option for a specific subset of HIV pa…
Aug 27, 2026 Corporate Catalyst Bullish Impact 75
Gilead Sciences Announces FDA Approval For Bixlenvo, The Smallest Once-Daily Single Tablet Regimen For The Treatment Of HIV In Adults Who Are Virologically Suppressed
Gilead Sciences has secured FDA approval for Bixlenvo, a novel single tablet regimen for HIV. This is significant as Bixlenvo is the smallest once-daily STR and specifically target…
Aug 24, 2026 Corporate Catalyst Bullish Impact 75
Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Gilead Sciences announced the European Commission's marketing authorization for its Trodelvy-Keytruda combination therapy for first-line metastatic triple-negative breast cancer (T…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123
RBC Capital analyst Brian Abrahams updated his coverage on Gilead Sciences, maintaining a 'Sector Perform' rating but raising the price target from $120 to $123. This adjustment re…
Aug 5, 2026 Corporate Catalyst Neutral Impact 55
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target
Needham analyst Joseph Stringer reiterated a 'Buy' rating and maintained a $170 price target for Gilead Sciences. This action signals continued confidence from a prominent analyst …
Aug 4, 2026 Corporate Catalyst Bullish Impact 75
Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway For Anito-Cel Cell Therapy, With Five Months To Go Until FDA PDUFA Date; Do Not Currently Anticipate Pursuing Additional Sizable M&A Transactions This Year
Gilead Sciences announced an upward revision of its full-year HIV growth expectations from 8% to 9%-10% year-over-year. This is a significant positive development for the company, …
Aug 4, 2026 Corporate Catalyst Bearish Impact 85
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est
Gilead Sciences has announced a significant reduction in its GAAP EPS guidance for FY2026, moving from a range of $(3.25)-$(2.85) to $(3.75)-$(3.40). This new guidance is considera…
Aug 4, 2026 Corporate Catalyst Neutral Impact 75
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est
Gilead Sciences (GILD) has raised its FY2026 adjusted EPS guidance from a range of $(1.05)-$(0.65) to $(0.65)-$(0.30), significantly narrowing the loss and improving the outlook co…
Aug 4, 2026 Corporate Catalyst Bearish Impact 92
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate
Gilead Sciences announced Q2 adjusted EPS of $(6.75), which, while a loss, significantly beat the analyst consensus of $(7.24). This beat, despite being a 435.82% decrease from the…
Jul 24, 2026 Corporate Catalyst Bullish Impact 75
Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer
Gilead's Trodelvy, in combination with Merck's Keytruda, received a positive opinion from the EMA's CHMP for first-line treatment of PD-L1 positive metastatic triple-negative breas…
Jul 21, 2026 Corporate Catalyst Bearish Impact 75
Gilead Sciences shares are trading lower after Leerink Partners downgraded its rating on the stock from Outperform to Market Perform and lowered its price target from $146 to $127.
This headline represents a significant corporate catalyst for Gilead Sciences. Analyst downgrades, especially from 'Outperform' to 'Market Perform' with a substantial price target …
Jul 21, 2026 Corporate Catalyst Bullish Impact 85
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
Gilead Sciences and Merck & Co. have reported detailed Phase 3 results for their once-weekly oral HIV regimen, ISL/LEN, showing it maintained viral suppression and was non-inferior…
Jul 21, 2026 Corporate Catalyst Bearish Impact 65
Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127
Leerink Partners' analyst Daina Graybosch downgraded Gilead Sciences (GILD) from an 'Outperform' rating to 'Market Perform' and significantly lowered the price target from $146 to …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.